Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
Authors
Keywords
-
Journal
Biomed Research International
Volume 2018, Issue -, Pages 1-8
Publisher
Hindawi Limited
Online
2018-11-06
DOI
10.1155/2018/5698212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
- (2018) Manali Mukherjee et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Type 2 immunity in asthma
- (2018) Marco Caminati et al. World Allergy Organization Journal
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- IL-33 mediates reactive eosinophilopoiesis in response to airborne allergen exposure
- (2016) E. L. Anderson et al. ALLERGY
- Measuring Eosinophils to Make Treatment Decisions in Asthma
- (2016) Parameswaran Nair et al. CHEST
- Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
- (2016) Jonathan Corren et al. CHEST
- Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
- (2016) Leif Bjermer et al. CHEST
- Molecular diagnosis and precision medicine in allergy management
- (2016) Anna Maria Riccio et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- An overview on safety of monoclonal antibodies
- (2016) Andrea Matucci et al. Current Opinion in Allergy and Clinical Immunology
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders
- (2016) Gilda Varricchi et al. Current Opinion in Allergy and Clinical Immunology
- The safety of monoclonal antibodies in asthma
- (2016) Giovanni Passalacqua et al. Expert Opinion On Drug Safety
- A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma
- (2016) Diego Bagnasco et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Assessing biomarkers in a real-world severe asthma study (ARIETTA)
- (2016) Roland Buhl et al. RESPIRATORY MEDICINE
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
- (2016) Gilda Varricchi et al. Therapeutic Advances in Respiratory Disease
- A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma
- (2015) Richard M. Nowak et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
- (2015) Laura De Ferrari et al. Expert Review of Respiratory Medicine
- Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2014) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients
- (2014) Pierluigi Mauri et al. IMMUNOLOGY LETTERS
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
- (2014) Mario Castro et al. Lancet Respiratory Medicine
- Anti-IL5 therapy for asthma and beyond
- (2014) Manali Mukherjee et al. World Allergy Organization Journal
- The consequences of not having eosinophils
- (2013) G. J. Gleich et al. ALLERGY
- Exploring the Effects of Omalizumab in Allergic Asthma
- (2013) Nicola A. Hanania et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Type 2 innate lymphoid cells control eosinophil homeostasis
- (2013) Jesse C. Nussbaum et al. NATURE
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Reslizumab for Poorly Controlled, Eosinophilic Asthma
- (2011) Mario Castro et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
- (2009) Prescott G. Woodruff et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
- (2009) Pranabashis Haldar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
- (2009) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started